Precision BioSciences ( (DTIL) ) has shared an update.
Precision BioSciences has received clearance in Moldova to begin clinical trials for its gene editing program, PBGENE-HBV, aimed at treating chronic hepatitis B. The innovative approach targets the root cause of the disease by eliminating cccDNA, potentially leading to functional cures. This milestone marks a significant step forward in their global clinical strategy, as they aim to provide a groundbreaking treatment for millions affected worldwide.
See more insights into DTIL stock on TipRanks’ Stock Analysis page.